nach oben

Erschienen in:

01.02.2014 | originalarbeit

Österreichische 3e-Empfehlungen zu Diagnose und Management von Gicht 2013

verfasst von: Dr. Judith Sautner, MD, Johann Gruber, MD, PhD, Manfred Herold, MD, PhD, Jochen Zwerina, MD, PhD, Burkhard F. Leeb, MD, PhD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 3-4/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Grundlagen

Gicht ist die häufigste entzündliche Gelenkerkrankung in der westlichen Welt und zeigt eine steigende Prävalenz. Nach dem Vorbild früherer 3e-Empfehlungen (Evidence-Expertise-Exchange) zu anderen rheumatologischen Problemen war das jetzige Ziel die Erstellung von internationalen Empfehlungen zur Diagnose und Therapie von Gicht und Hyperuricämie auf Basis einer systematischen Literatursuche.

Methodik

Zu Beginn des 3e-Projektes wurden in den teilnehmenden Ländern in einem Delphi-Prozess zunächst jeweils 10 nationale Fragen erstellt, die dann zu 10 internationalen Fragen verknüpft wurden. Danach wurde eine systematische Literatursuche durchgeführt. Auf Basis dieser Literatur wurden in einem nächsten Schritt wieder zunächst nationale und in weiterer Folge daraus internationale Empfehlungen formuliert. Der Grad der Zustimmung wurde dokumentiert und die Antworten nach Evidenzgrad klassifiziert.

Ergebnisse

Ein österreichisches Expertengremium erstellte unter Zuhilfenahme der verfügbaren Literatur 10 Empfehlungen zu Diagnostik und Therapie der Gicht bzw. Hyperuricämie.

Nach Publikation der internationalen 3e-Empfehlungen präsentieren wir hier einen Überblick über die nationalen österreichischen Fragen und Experten-Empfehlungen zu Diagnostik und Therapie der Gicht 2013 sowie einen Vergleich der österreichischen mit den internationalen Empfehlungen.

Vorheriger Artikel COPD: an underdiagnosed disease at hospital environment

Nächster Artikel The role of intraoperative ultrasound in breast-conserving surgery of nonpalpable breast cancer

Li C, Hsieh MC, Chang SJ. Metabo lic syndrome, diabetes, and hyperuricemia. Curr Opin. Rheumatol. 2013 Mar;25(2):210–6.

Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008 Oct 23;359(17):1811–21.PubMedCentralPubMedCrossRef

Kaya MG, Uyarel H, Akpek M, et al. Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012;109(4):486–91.PubMedCrossRef

Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis.Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1301–11.PubMedCentralPubMedCrossRef

Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part II: Management.Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312–24.PubMedCentralPubMedCrossRef

Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 ACR guidelines for management of gout. Part I: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012 Oct;64(19):1431–46.CrossRef

Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 ACR guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2021 Oct;64(19):1447–61.CrossRef

Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2013, 10.1136/annrheumdis-2013–203325.

Janssens HJ, Janssen M, van den Lisdonk EH, et al. Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care. Ann Rheum Dis. 2010;69:1255–6.PubMedCrossRef

10.

Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol. 2009;15:22–4.PubMedCrossRef

11.

Glazebrook KN, Guimaraes LS, Murthy NS, et al. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. Radiology. 2011;261:516–24.PubMedCrossRef

12.

Lai KL, Chiu YM. Role of ultrasonography in diagnosing gouty arthritis. J Med Ultrasound. 2011;19:7–13.CrossRef

13.

Bhole V, Choi JW, Kim SW, et al. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med. 2010 Oct;123(10):957–61.PubMedCentralPubMedCrossRef

14.

Hozawa A, Folsom AR, Ibrahim H, et al. Serum uric acid and risk of ischemic stroke: the ARIC Study. Atherosclerosis. 2006 Aug;187(2):401–7.PubMedCrossRef

15.

Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006 Jun;37(6):1503–7.PubMedCrossRef

16.

Kuo CF, See LC, Luo SF, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology. 2010 Jan;49(1):141–6.PubMedCrossRef

17.

Kuo CF, See LC, Yu KH, et al. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology. 2013 Jan;52(1):127–34.PubMedCrossRef

18.

Strasak AM, Rapp K, Hilbe W, et al. VHM & PP Study Group. The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28000 older Austrian women. Ann Oncol. 2007 Nov;18(11):1893–7.PubMedCrossRef

19.

Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009 Feb;169(4):342–50.PubMedCentralPubMedCrossRef

20.

Janssens HJ, Jannse M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371:1854–60.PubMedCrossRef

21.

Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: 24h outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060–8.PubMedCrossRef

22.

Willburger RE, Mysler E, Derbot J, et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology. 2007;46(7):1126–32.PubMedCrossRef

23.

Choi HK, Atkinson K, Karlson E, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350:1093–103PubMedCrossRef

24.

Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336:309–12.PubMedCentralPubMedCrossRef

25.

Dalbeth N, Wong S, Gamble GD, et al. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann Rheum Dis. 2010 69(9):1677–82.

26.

Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficay and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):63.

27.

Singh JA;Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008 Sep;67(9):1310–6.PubMedCrossRef

28.

Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429–32.PubMed

29.

Paulus HE, Schlosstein LH Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout. A placebo controlled study od probenecid-treated pateints. Arthritis Rheum. 1974;17(5):609–14.PubMedCrossRef

30.

Schlesinger N, Mysler E, Lin HY, et al. Cnakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264–71.PubMedCentralPubMedCrossRef

31.

Karimzadeh H, Nazari J, Mottaghi P, Kabiri P. Different duration of colchicine for preventing recurrence of gouty arthritis. J Res Med Sci. 2006;11(2):104–7.

32.

Stamp LK, O’Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412–21.PubMedCrossRef

33.

Ohue T, Yamamoto T, et al. Effects of allopurinol and benzbromarone on renal clearance of creatinine and uric acid in gouty patients. Japanese J Rheumatology. 1991;3(1):21–7.

34.

De Angelis S, Noce A, Di Renzo L, et al. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind- randomized study. Eur Rev Med Pharmacol Sci. 2007;11:179–84.

35.

Jordan KM, Cameron S, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout on behalf of the British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). Rheumatology. 2007;26:1372–74.CrossRef

36.

Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum. 2006;55(5):786–90.PubMedCrossRef

37.

Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321–25.

38.

Dalbeth N, McQueen FM, Singh JA, et al. Tophus measurement as an outcome measure for clinical trials of chronic gout: Progress and research priorities. J Rheumatol. 2011;38(7):1458–61.PubMedCrossRef

39.

Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol. 2007;34(9):1888–93.PubMed

40.

Khanna PP, Perez-Ruiz F, Maranian P, Khanna D. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology. 2011;50(4):740–45.PubMedCentralPubMedCrossRef

41.

Taylor WJ, Colvine K, Gregory K, et al. The Health Assessment Questionnaire Disability Index is a valid measure of physical function in gout. Clin Exp Rheumatol. 2008;26(4):620–26.PubMed

42.

Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase fort he treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711–20.PubMedCrossRef

43.

Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273–82.PubMedCrossRef

44.

Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophy in chronic gout. Arthritis Rheum. 2002;47(4):356–60.PubMedCrossRef

45.

Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987 Mar;82(3):421–6.PubMedCrossRef

46.

Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011;6(8):1887–94.PubMedCentralPubMedCrossRef

47.

Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39(4):1227–33.PubMedCrossRef

48.

Siu YP, Leung KT, Tong MK and Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006 Jan:47(1):51–9.PubMedCrossRef

49.

Perez-Ruiz F, Carmona L, Yebenes MJ, et al. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study. J Clin Rheumatol. 2011;17:349–55.PubMedCrossRef

50.

Haindl PM, Rintelen B, Brezinschek HP, et al. Österreichische Empfehlungen zum Gebrauch von Methotrexat in der Rheumatologie – Expertenkonsensus basierend auf einer systematischen Literatursuche. Akt Rheumatol. 2010;35:251–9.CrossRef

Titel: Österreichische 3e-Empfehlungen zu Diagnose und Management von Gicht 2013
verfasst von: Dr. Judith Sautner, MD
Johann Gruber, MD, PhD
Manfred Herold, MD, PhD
Jochen Zwerina, MD, PhD
Burkhard F. Leeb, MD, PhD
Publikationsdatum: 01.02.2014
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 3-4/2014
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-013-0469-1

Springer Medizin Österreich

Zusammenfassung

Grundlagen

Methodik

Ergebnisse

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3-4/2014

ÖGIM Flip

The role of intraoperative ultrasound in breast-conserving surgery of nonpalpable breast cancer

Researcher of the Month

Serum creatinine elevation caused by bupropion

Rhabdomyolysis in influenza A/H1N1

Evaluation of treatment responses and colony-forming progenitor cells in 50 patients with aplastic anemia after immunosuppressive therapy or hematopoietic stem cell transplantation: a single-center experience